ArticleCancer research2008
Inactivation of gadd45a sensitizes epithelial cancer cells to ionizing radiation in vivo resulting in prolonged survival.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A.Journal of translational medicine · 2024Article
- Impact of GADD45A on Radiation Biodosimetry Using Mouse Peripheral Blood.Radiation research · 2023Article
- Pulsed low dose-rate irradiation response in isogenic HNSCC cell lines with different radiosensitivity.Radiology and oncology · 2020Article
- Injury Activates a Dynamic Cytoprotective Network to Confer Stress Resilience and Drive Repair.Current biology : CB · 2019Article
- GADD45α sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level.Cell death & disease · 2018Article
- GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.Scientific reports · 2017Article
- TRAF6 Restricts p53 Mitochondrial Translocation, Apoptosis, and Tumor Suppression.Molecular cell · 2016Article
- Transcriptome analysis of glioma cells for the dynamic response to γ-irradiation and dual regulation of apoptosis genes: a new insight into radiotherapy for glioblastomas.Cell death & disease · 2013Article
- LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells.Cellular and molecular neurobiology · 2013Article
- Normal prostate-derived stromal cells stimulate prostate cancer development.Cancer science · 2011Article
- Identification of radiation-induced expression changes in nonimmortalized human T cells.Radiation research · 2011Article
- Over-expression of Gadd45a enhances radiotherapy efficacy in human Tca8113 cell line.Acta pharmacologica Sinica · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Ionizing radiation (IR) therapy is one of the most commonly used treatments for cancer patients. The responses of tumor cells to IR are often tissue specific and depend on pathway aberrations present in the tumor. Identifying molecules and mechanisms that sensitize tumor cells to IR provides new potential therapeutic strategies for cancer treatment. In this study, we used two genetically engineered mouse carcinoma models, brain choroid plexus carcinoma (CPC) and prostate, to test the effect of inactivating gadd45a, a DNA damage response p53 target gene, on tumor responses to IR. We show that gadd45a deficiency significantly increases tumor cell death after radiation. Effect on survival was assessed in the CPC model and was extended in IR-treated mice with gadd45a deficiency compared with those expressing wild-type gadd45a. These studies show a significant effect of gadd45a inactivation in sensitizing tumor cells to IR, implicating gadd45a as a potential drug target in radiotherapy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.